A Lesson to Learn o...
Health Care: Drugs
Isis Pharmaceuticals (ISIS: NASDAQ)
$22.58 -0.50 | -2.17%
06/19/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -65.48M | -84.80M | -61.25M | 150.67M |
| Operating Gains/Losses | -13.64M | -628.00K | 2.87M | -2.08M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 6.40M | -5.68M | 10.48M | -6.78M |
| (Increase) Decrease in Inventories | -1.98M | -1.66M | 284.00K | -17.00K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 1.29M | 875.00K | 1.32M | -3.65M |
| (Decrease) Increase In Other Current Liabilities | -4.56M | 8.62M | -5.77M | -10.07M |
| (Increase) Decrease In Other Working Capital | 49.06M | -69.56M | -47.75M | -83.60M |
| Other Non-Cash Items | 285.00K | 11.77M | 13.67M | -171.85M |
| Net Cash From Continuing Operations | 1.88M | -114.80M | -63.59M | -108.44M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 1.88M | -114.80M | -63.59M | -108.44M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 10.33M | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 242.66M | 488.92M | 577.53M | 578.89M |
| Purchases of Property, Plant & Equipment | -5.17M | -11.00M | -17.56M | -16.29M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -217.88M | -371.11M | -530.14M | -776.38M |
| Other Cash from Investing Activities | -3.00M | 0.00 | -16.23M | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 18.00M | 110.90M | 23.69M | -212.29M |
| Issuance of Debt | 203.80M | 1.62M | 4.69M | 6.39M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 9.47M | 3.57M | 4.36M | 13.16M |
| Repayment of Long-Term Debt | -174.14M | -5.86M | -4.35M | -2.83M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 185.28M |
| Net Cash From Financing Activities | 39.13M | -672.00K | 4.70M | 202.00M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 59.00M | -4.58M | -35.20M | -118.73M |
Portfolios with ISIS
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- UserCy Winther
- ContributorDrugs Facing FDA Approval i...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Under-$10 Setting Up...
- ContributorUnder-$10 Setting Up To Tra...
- UserNext Generation
- Contributor10 Biotech Stocks on Clinic...
Latest ISIS Headlines from TheStreet
- Isis Stock Hits New 52-Week High (ISIS) 06.11.13 | 10:06 am
- 'Mad Money' Lightning Round: Green Mountain Coffee's Too Hot 06.05.13 | 06:06 am
- Cramer's 'Mad Money' Recap: Hiders and Seekers 06.04.13 | 07:06 pm
- Isis Stock Falls On Unusually High Volume (ISIS) 05.08.13 | 04:05 pm
- Isis Reaches New 52-Week High (ISIS) 05.03.13 | 10:05 am
- Cramer's 'Mad Money' Recap: Good Earnings, Bad Market 05.01.13 | 08:05 pm
- Isis Stock Hits New 52-Week High (ISIS) 04.19.13 | 09:04 am
- Cramer's 'Mad Money' Recap: Risk vs. Reward 04.03.13 | 08:04 pm
- Biotech Stock Mailbag: Celsion, Navidea, AP Pharma, Sarepta 02.01.13 | 07:02 am
- 4 Stocks Rising on Big Volume 01.31.13 | 08:01 am
Press Releases for ISIS
- Isis Pharmaceuticals To Present A General Corporate Update At Its 2013 Annual Meeting Of Stockholders And Open House - PR Newswire 06.18.13 | 07:06 am
- Xenon Licenses Antisense Drug XEN701 From Isis And Initiates Preclinical Toxicology Studies - PR Newswire 06.10.13 | 07:06 am
- Isis Pharmaceuticals Earns $6 Million Payment From AstraZeneca - PR Newswire 06.06.13 | 07:06 am
- Isis Pharmaceuticals To Present At The Goldman Sachs 34th Annual Global Healthcare Conference - PR Newswire 06.05.13 | 07:06 am
- Isis Pharmaceuticals Announces Exercise Of Underwriters' Option To Purchase Additional Shares - PR Newswire 05.31.13 | 04:05 pm
- Isis Pharmaceuticals To Present At The Deutsche Bank 38th Annual DbAccess Health Care Conference - PR Newswire 05.23.13 | 07:05 am
- Isis Pharmaceuticals To Present At The 2013 UBS Global Healthcare Conference - PR Newswire 05.13.13 | 07:05 am
- Isis Pharmaceuticals Earns $3.5 Million From Biogen Idec - PR Newswire 05.09.13 | 04:05 pm
- Isis Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference - PR Newswire 05.09.13 | 02:05 pm
- Isis Pharmaceuticals Prices Public Offering Of Common Stock - PR Newswire 05.08.13 | 09:05 pm
Partner Headlines for ISIS
- Isis Pharmaceuticals Inc (ISIS): Today's Most Compelling Stock Buy - NASDAQ 05.17.13 | 05:05 pm
- Cree, Seagate, Sandisk: Why Richie Freeman Likes Them - Investor's Business Daily 04.02.13 | 06:04 pm
- Isis Pharma Issues Update on CHMP Opinion on KYNAMRO - Benzinga 03.22.13 | 02:03 pm
- Revenues Decline at Alnylam - Analyst Blog - Zacks 11.07.12 | 09:11 am
- Isis Pharmaceuticals To Receive $1.1 Million From Alnylam - Benzinga 10.23.12 | 01:10 pm
- Benzinga Mid-Day Market Update - Benzinga 10.17.12 | 12:10 pm
- UPDATE: Piper Jaffray Downgrades ISIS Pharmaceuticals to Neutral on FDA Briefing - Benzinga 10.16.12 | 01:10 pm
- Alnylam-ISIS Venture Prices IPO - Analyst Blog - Zacks 10.05.12 | 06:10 pm
- Alnylam/Isis's Regulus to Go Public - Analyst Blog - Zacks 08.22.12 | 07:08 pm
- Biogen Inks Deal with Regulus - Analyst Blog - Zacks 08.16.12 | 06:08 pm
